5-(2-ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine
- $252 - $904
- Product name: 5-(2-ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine
- CAS: 337310-80-2
- MF: C12H15N3OS
- MW: 249.33
- EINECS:
- MDL Number:MFCD01821405
- Synonyms:5-(2-ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine;1,3,4-Thiadiazol-2-amine, 5-(2-ethoxyphenyl)-N-ethyl-
4 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Crysdot
- Matrix Scientific
Package
- 5MG
- 500mg
- 1g
- 5g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0979821
- Product description5-(2-ETHOXYPHENYL)-N-ETHYL-1,3,4-THIADIAZOL-2-AMINE 95.00%
- Packaging5MG
- Price$500.95
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11141431
- Product description5-(2-Ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine 97%
- Packaging1g
- Price$320
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11141431
- Product description5-(2-Ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine 97%
- Packaging5g
- Price$904
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number039899
- Product description5-(2-Ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine
- Packaging500mg
- Price$252
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | CHM0979821 | 5-(2-ETHOXYPHENYL)-N-ETHYL-1,3,4-THIADIAZOL-2-AMINE 95.00% | 5MG | $500.95 | 2021-12-16 | Buy |
Crysdot | CD11141431 | 5-(2-Ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine 97% | 1g | $320 | 2021-12-16 | Buy |
Crysdot | CD11141431 | 5-(2-Ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine 97% | 5g | $904 | 2021-12-16 | Buy |
Matrix Scientific | 039899 | 5-(2-Ethoxyphenyl)-N-ethyl-1,3,4-thiadiazol-2-amine | 500mg | $252 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|